Figure Legend
Epithelial plasticity in 3D cultures. Epithelial cells (MDCK) form ducts when grown on 3D-matrices resembling the in vivo microenvironment (top). When grown under identical conditions, MDCK cells expressing Prrx1 (an EMT inducer) form networks of mesenchymal cells (bottom). Note the dramatic phenotypic change that is accompanied by the acquisition of motility and invasive properties. Blue, nuclei revealed by DAPI staining; Red, Actin filaments as seen after phalloidin binding; Green, E-cadherin (epithelial marker) in top panel and Vimentin (mesenchymal marker) in bottom panel. 2 by the activation of one or several transcription factors belonging to different families including Snail, Twist, Zeb and others (4) , generally termed EMT-TFs (5). These EMT-TFs elicit the EMT program by repressing the epithelial phenotype, enhancing mesenchymal traits including motility and inducing the ability to degrade the basement membrane and the extracellular matrix in general. In addition, they also impinge into other basic cellular processes that help maintain the mesenchymal phenotype, the efficacy of migration and to survive in adverse environments. As such, EMT-TFs attenuate proliferation and protect from cell death activating survival signaling cascades (2) (Figure 1 ). Due to the pivotal role of E-cadherin loss, EMT-TFs are sometimes referred to as E-cadherin repressors and also, a decrease in functional Ecadherin is often associated with the activation of EMT. However, it is important to bear in mind that the EMT program and EMT-TFs are much more than E-cadherin transcriptional repressors, that E-cadherin downregulation (or endocytosis) is not necessarily associated with the EMT program and that E-cadherin re-expression is not sufficient to revert the fibroblastic phenotype (6) .
When cells that escape from carcinomas are converted into mesenchymal cells with migratory and invasive properties, this can be considered an EMT (2, 3) and many EMT-TFs have been characterized that operate during tumor progression (7) . However, the relevance of the EMT in cancer biology has been a matter of debate (8) . The application of sophisticated imaging techniques to animal models and the characterization of circulating tumor cells (CTCs) from patients as cell with an EMT signature have provided evidences that the EMT also occurs during the dissemination of cells from a primary tumor (9) (10) (11) (12) .
Since the EMT can also endow cells with stem cell properties, and given that cancer can be initiated, maintained and propagated by stationary and motile cancer stem cells (CSC; 5, 13), a new field of study has emerged that requires the concerted effort of developmental biologists and cancer researchers. However, even though developmental and pathological EMTs have many common features they also have obvious differences, leading to the classification of three different EMT types (14) .
Type 1 refers to developmental EMTs, type 2 to those related to wound healing, tissue regeneration and organ fibrosis and type 3 refers to the EMT associated with cancer.
Developmental EMTs imply the conversion of epithelial into mesenchymal cells, but embryos lack inflammatory responses, typical of Type 2 and 3 EMTs that occur in the adult (14, 15) . Type 2 EMT is also characterized by the appearance of myofibroblasts with the ability to secrete an excess of extracellular matrix molecules in response to inflammation (14) . In contrast to the situation in embryos, in cancer cells and during regeneration, the acquisition of a mesenchymal state in fibrosis can be considered as an end stage, which leads to organ degeneration and failure (Figure 1 ). During cancer progression, tumor cells undergo type 3 EMT, which in addition to invasion and motility involves intravasation of delaminated cells into lymphatic and blood vessels, and their subsequent extravasation. The intravasation and extravasation steps do not occur in fibrosis and do have obvious parallels with the migratory processes undergone by embryonic cells. In this review I will focus on the similarities, in particular between embryonic and cancer cells, and how the latter rely upon developmental programs, not only to delaminate from the initial tumor but also, to later colonize distant sites.
The common theme of epithelial cell plasticity unifies both events.
Global cellular programs regulate epithelial plasticity
EMT is triggered by many extracellular signals and agents both in embryos and in cancer cells. The most potent inducers are members of the TGFβ/BMP family, but also Wnt, Notch, epidermal growth factor (EGF), fibroblast growth factor (FGF), hypoxia, obesity, alcohol, nicotine, UV light and others (reviewed in 2). Such pathways and agents may act alone or in combination, and the response is dependent on the cell context (2) . The response to such signals converges on the activation of the EMT-TFs, which can cooperate to induce or maintain the mesenchymal phenotype (4, 16) . The existence of many EMT-TFs provides robustness to the system ensuring the implementation of the EMT program during embryonic development (1, 17) . Analyzing regions where EMT is induced in embryos indicates that Snail expression normally precedes the expression of other factors, which are more relevant for the maintenance of the mesenchymal phenotype (2, 4) . This temporal hierarchy of EMT-TF activation and cooperation and also seem to operate in tumors, as observed for Snail factors and 4 Twist in breast epithelial cells and breast cancer progression (16, (18) (19) (20) . Once activated, EMT-TFs can, in turn, activate the same signaling pathways to generate positive regulatory autocrine loops that help maintain the mesenchymal phenotype both in normal and transformed breast stem cells (21) .
Since EMT may be extremely deleterious when aberrantly activated in the adult are not able to intravasate into blood vessels, to later develop blood-borne distant metastasis (33) .
Reversal of developmental EMTs for organ formation
As noted above, developmental EMTs are reversible (34) . As such, the cells that go through so called primary EMTs in the embryo later undergo the reverse process, MET, in order to differentiate into multiple cell types. Early mesodermal cells, generated by EMT and located at different medio-lateral levels of the embryo (axial, paraxial, intermediate and lateral plate mesoderms), condense into transient epithelial structures through MET to give rise to the notochord, the somites, the primordia of the urogenital system, and the splanchopleura and somatopleura, respectively ( Figure 3 ).
In the majority of these structures a second round of EMT is completed. For example, the dorsal somite converts into the dermal and myotomal mesenchyme, which will give rise to components of the dermis and the muscle satellite cells. The ventral part will become the mesenchymal sclerotome that later generates the vertebrae, the ribs and the tendons (Figure 3 36) , in mouse models of renal fibrosis (37) and in cancer cells (38) .
Eph/Ephrin signaling is also involved in the epithelialization of somites (39) and Wnt signaling is required for MET during nephron development (40).
For nearly all MET processes, there is a concomitant downregulation of the corresponding EMT-TFs (i.e. 41, 42). This downregulation is accompanied by the appearance of specific epithelial markers that are associated with differentiation into the distinct tissues and organs. In the case of the epithelialization of the somitic and pronephric tissues, MET is associated with the induction of Paraxis and Pax2, respectively.
Reversal of EMTs for metastatic colonization
Despite the observations above, it is not universally accepted that tumor cell dissemination is related to a change in cell identity (i.e. a requirement for EMT, see 8) but rather, it might rely on mutations that weaken the cell-cell adhesion of cancer cells. Nevertheless, it is clear that carcinoma metastases usually adopt a welldifferentiated epithelial phenotype. Ironically, this is one of the arguments used to dismiss the importance of the EMT in cancer progression. However, the differentiated phenotype of metastases reflects the epithelial plasticity implicated in tumor progression, in order words, the reversion of EMT firstly suggested by Brabletz and colleagues (43) and again resembling the situations described during embryonic development (34) . MET induction by miR-200 was shown to promote breast cancer metastasis (57) in agreement with earlier findings indicating that MET facilitates bladder cancer metastasis (58) and the observation that myeloid cells induce a MET in the metastatic niche (59) . However, until very recently a requirement for epithelial plasticity and the reversion of EMT had yet to be directly assessed in vivo.
In an elegant study using a spontaneous squamous cell carcinoma model in mice carrying skin-specific inducible Twist, it was shown that Twist-mediated EMT is sufficient to promote the dissemination of cancer cells into the bloodstream. Yet more importantly, it was shown in this model that Twist needs to be downregulated for metastasis to occur (60) . Further in vivo evidence for epithelial plasticity and the requirement of MET has been found in the progression of breast cancer to the metastatic state. EMT mediated by an EMT-TF, the homeobox and paired-related Prrx1 factor, needs to be reverted, and Prrx1 loss is required for metastatic colonization (16) .
Therefore, a reversible EMT seems to be necessary for the metastasis of primary carcinomas, revealing a developmental program that is reactivated by cancer cells in order for them to successfully complete the final step of the metastatic cascade, the formation of macrometastasis.
Uncoupling EMT and stemness
It has been found that EMT can confer stem-like properties on cells (61, 62) . This is consistent with the concept of "migratory cancer stem cells" (63) and provides a link between the EMT program and the characteristics associated with cancer stem cells 9 (CSC), i.e. self-renewal and the capacity to seed secondary tumors and produce differentiated non-stem cells (5) . However, the relationship between EMT and stemness is another controversial issue in tumorigenesis, as it was later shown that fibroblasts must undergo a MET to complete the initial reprogramming of fibroblasts to iPSCs (36, 64) . Again, help may come from development, although CSCs differ from canonical embryonic stem cells (ESCs) in that they only revert to the phenotypes of the primary tumor and therefore, they have a more restricted potency than both ESCs and iPSCs (65) . initially involve the acquisition of stemness, which represents a later event (36) . In addition, one of the EMT-TFs, Snail2, cooperates with Sox9 in the acquisition of the mesenchymal mammary stem cell state, although it seems that Snail2 is mainly involved in the induction of EMT and Sox9 is responsible for the entry into the stem cell state (68) . Further evidence of such independent regulation comes from the analysis of Prrx1, which unlike "classical EMT-TFs" (Snail, Twist, Zeb factors) induces EMT without concomitantly inducing CSC properties. By contrast, it is the loss of Prrx1 that facilitates self-renewal and mammosphere-forming ability in breast cancer cells (16) , simultaneously inducing MET and tumor-initiating capacity, both favoring metastatic colonization. How Prrx1 downregulation is achieved at the metastatic niche and how tumor initiating capacity is maintained upon the downregulation of EMT-TFs linked to stemness (Snail-type) is a matter of future investigation ( Figure 5 ). Another pending issue is whether the two EMT types are parallel or exclusive processes in a particular tumor. On the one hand, Prrx and Snail do not show any correlation in datasets from patients. However, Prrx1 and Twist are correlated, and in these cases, Prrx1 prevails (16) as PRRX downregulation is sufficient to induce MET and CSC properties. It is possible that both types (Snail and Prrx) could co-exist, as depicted in Figure 5 , but information is still lacking. On the other hand, isolated CTCs depict both EMT and CSC traits (10, 11) , suggesting that they might not include the Prrx1 type. This has not been specifically addressed but it is likely that in purified CTCs Prrx-positive cells are underrepresented, as they are fully mesenchymal and might have escaped isolation with current purification protocols, which use epithelial markers to identify CTCs (10,
11).
In summary, data accumulated over the last few years indicate that EMT-TFs are developmental factors that when aberrantly activated in tumors initiate the invasion-metastatic cascade. This finding also favors the cancer stem cell versus the clonal evolution model by which successive mutations accumulate in a tumor providing a defined phenotype (69) . However, two additional issues need to be discussed here.
On the one hand, stemness is also a plastic state during tumor progression whereby both stationary and migratory CSCs can co-exist (13).
On the other hand, there are different subsets of EMT-TFs that while all able to induce the mesenchymal phenotype, decrease proliferation and promote invasion, they can either provide or repress CSC properties (classical EMT-TFs vs Prrx1, respectively), or in other words, they can either promote or repress tumor initiating capacities. The bottom line is that (i) EMT-TFs need to be downregulated for metastasis to form, which implies reversion to the epithelial phenotype and increased proliferation ( Figure 5 ) and (ii) the regulation of stem cell properties is independent from that of epithelial plasticity. Indeed, malignancy by cancer cells require the reversion to the epithelial phenotype and the maintenance of a "stemness" state (70), which may be achieved when the Prrx1-type of EMT-TFs is repressed (16) and/or when Connective Tissue Growth Factor (CTGF), recently described as both MET inducer and stem-like properties enhancer, is activated in cancer cells (71) (Figure 5 ).
EMT/MET in cancer: Conflicting data or just plasticity?
The high degree of epithelial plasticity observed during cancer progression together with the independent regulation of EMT and stemness has several implications. EMT-related invasion plus dissemination is required but it is not sufficient for completing the metastatic cascade, and therefore invasive and metastatic may not be equivalent terms.
In agreement with the requirement for invasion and dissemination for metastasis formation, the presence of CTCs has prognostic and predictive value in breast cancer patients (72) . Accordingly, abrogating EMT-TFs such as Snail factors in cancer cells, make these cells less prone to invade and later generate metastasis when injected in mice (18) . However, constitutive expression of Snail or Twist also suppresses metastasis formation (60, 67) as EMT-TFs must be downregulated for metastasis to form (60, 16) . Rather than representing a paradox, these data simply reflect the plasticity of epithelia and the dynamics of the whole metastatic process, resembling that of embryonic cell migration to populate distant territories. Thus, while the EMT is associated with the early steps in metastasis, i.e. delamination, invasion and intravasation, it is not associated with metastatic colonization. Indeed, there is no association between the expression of Snail or Twist in primary tumors and relapsefree survival in patients with breast or lung squamous carcinomas (16) . This should be born in mind when referring to the role of different elements in tumor progression and, consequently, avoid the use of the term "invasive and metastatic" for factors involved in the acquisition of invasive properties by cancer cells. A similar situation applies when we contemplate embryonic development. The EMT-TFs are expressed in the embryo wherever EMT processes take place. However, EMT-TFs are not expressed in the derivatives of these migratory populations, since once embryonic cells reach their destination to differentiate into distinct tissues, the EMT inducers are repressed.
Thus, EMT-TFs are related to cell behavior rather than to cell fate and hence, their expression is only transient. Accordingly, EMT-TFs cannot be used as markers of differentiated cell populations, the equivalent of differentiated distant metastases.
The description of signals that downregulate EMT-TFs at the metastatic sites awaits further investigation but it is clear that interactions between CSCs and the tumor microenvironment dictate both EMT/invasion of the primary tumor (73, 74) and colonization at the metastatic niche (57, 58, 74) . The EMT program also seems to help recently extravasated cells to extend filopodium-like protrusions (FLPs), to interact productively with the niche, promoting homing and proliferation (75) . Cytokines are important to modify both microenvironments as they are fundamental to recruit mesenchymal stem cells (MSCs) and inflammatory cells. Indeed, the stroma influences metastasis formation and recent data point to the regulation of TGFβ/BMP signaling in both the primary tumor and the metastatic niche in colorectal and breast carcinomas (33, 76, 77) .
Towards improved metastatic therapeutic strategies
Cell plasticity and heterogeneity in tumor biology also has an impact on the design of therapeutic strategies (69) . Classical cytotoxic chemotherapy has proven beneficial in patients with carcinoma. However, one of the main caveats is the appearance of tumor recurrence, associated with acquired multidrug resistance and concomitant with the appearance of signs of EMT and stemness in the residual or relapsed tumor after chemotherapy. Indeed, resistance to cell death is a property of embryonic migratory cells upon undergoing EMT, implemented to promote their arrival to their destination (78) . A similar strategy is used by cancer stem cells and therefore, efforts are being devoted to fighting not only proliferation but also EMT and stem cell-like properties to prevent the metastatic disease in cancer patients.
To target the EMT, the strategy has been to inhibit some of its inducing signaling pathways including those of EGFR, PDGFR and TGF-β. Recent data indicate that inhibiting the TGF-β pathway might be beneficial in colorectal cancer metastatic disease (77) . But even if the bulk of the tumor can be significantly decreased, chemoresistant stem cells will support the subsequent growth of the tumor. 13 Therefore, different strategies have been used to directly target CSCs, including inhibitors of additional pathways such as those triggered by the developmental factors Notch, Wnt and Shh, using cytoprotective agents and/or small molecules identified in high-throughput screenings.
Recent data indicate that not only stem cells can generate differentiated cells but also that adult normal and (non-stem) cancer cells can re-enter the stem state, pointing to a bidirectional conversion between stem and non-stem populations (79, 80) ( Figure 5 ). This additional plasticity seems to be dependent on the chromatin state of the Zeb1 promoter, which is in a bivalent state in non-CSCs so that it can be rapidly activated in response to EMT inducing signals to help the conversion of non-CSCs into CSCs (81) (Figure 4) . Thus, there is a need to adjust therapeutic strategies to this superimposed level of cellular plasticity, as combating CSC is unlikely to be sufficient as new stem cells can be generated from the remaining differentiated tumor cells. The idea is to combine classical chemotherapy with anti-CSC drugs to simultaneously hit non-stem cells and CSC in a tumor.
Finally, it is clear that fully preventing delamination from the primary tumor will impede metastasis, which is the principle that has inspired efforts by academia and pharmaceutical companies to block the EMT. A recent report shows that this seems to be a valid strategy, as observed in a mouse model of ovarian carcinoma (28) .
Nonetheless, in the light of recent data on epithelial plasticity during metastatic colonization, and the need for cancer cells to revert to the epithelial phenotype through a MET (16, 60) , rather than preventing metastasis, inhibiting EMT could favor the formation of secondary tumors from already disseminated cells. This is particularly important in carcinomas where EMT is a very early event in tumorigenesis, where cancer cells have already disseminated before the tumor is diagnosed, as in pancreatic and breast carcinomas (82, 83) . In contrast, as EMT reversion does not happen during the development of the fibrotic disease, therapeutic intervention inhibiting EMT is a promising strategy to ameliorate fibrosis and organ degeneration (37) .
In summary, recent advances reveal an unanticipated degree of cell plasticity MDCK-Prrx1 cells were cultured and images processed as control cells (see Movie S1 legend).
